Pathalys

Series-B+
pathalys.com Biotech & Healthcare
Total Funding Undisclosed
Latest Round Undisclosed Series-B+
Last Announced Aug 20, 2024
Investors Undisclosed
Decision Makers 6 Verified

About Pathalys

At Pathalys Pharma, Inc. we are committed to improving the lives of patients through the development of enhanced therapeutics that improve the management of chronic kidney disease (CKD).

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Undisclosed
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website pathalys.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile @PathalysPharma (9 followers) Created on Feb 2022
LinkedIn Corporate Not linked

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Series-B+ announced

    fundraisingfox.com

  2. Milestone

    X account created (@PathalysPharma)

    9 followers

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Pathalys.

Funding History

1 Round
Series-B+ · Aug 20, 2024

Founders & Leadership

1

BT Slingsby

Co-Founder and Executive Chairman

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts